Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Topical travoprost
Travoprost · 1 trial · 1 indication
Number of subjects with Adverse Events including intra-operative and post-operative events (TEAE's) in the study eye
| Arm | Type | Description |
|---|---|---|
| Implantation and Exchange | EXPERIMENTAL | Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision. |
| Name | Type | Description |
|---|---|---|
| Travoprost | DRUG | Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision |
Inclusion Criteria: * Able and willing to attend scheduled follow-up exams for the duration of the study * Able and willing to provide written informed consent on the IRB (institutional review board)/IEC (institutional ethics committee)-approved Informed Consent form * Best spectacle corrected visu...
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
Travoprost is a small molecule prostaglandin F2-alpha receptor agonist developed by Glaukos Corporation (ticker GKOS) as an intraocular implant for open angle glaucoma. It is in Phase 2 clinical development and is designed to lower intraocular pressure in patients with this condition.
Travoprost is being developed for open angle glaucoma, a condition in which elevated intraocular pressure can damage the optic nerve. The investigational intraocular implant is intended to deliver the drug directly into the eye to manage this pressure. It has not been approved for this use.
Travoprost targets PTGFR, the prostaglandin F2-alpha receptor. It acts as an agonist at this receptor, meaning it activates the receptor to increase aqueous humor outflow from the eye, which lowers intraocular pressure. This mechanism underlies its development for open angle glaucoma.
Travoprost is being developed by Glaukos Corporation, which trades under the ticker GKOS. The company is investigating the drug as an intraocular implant for open angle glaucoma. The asset is currently in Phase 2 clinical development.
Travoprost is in Phase 2 clinical development. It is an investigational product and has not been approved by the FDA for any indication. The Phase 2 program has completed one trial, and no active trials are currently listed.
Travoprost has been studied in one completed Phase 2 trial, NCT04615403, titled Study of Exchange of Travoprost Intraocular Implant. The trial enrolled 33 participants with open angle glaucoma across sites in the United States and the Philippines. It was an uncontrolled study without randomization or blinding.